| Bronchitis, Chronic

Breyna vs Stiolto Respimat

Side-by-side clinical, coverage, and cost comparison for bronchitis, chronic.
Deep comparison between: Breyna vs Stiolto Respimat with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.
Safety signalsStiolto Respimat has a higher rate of injection site reactions vs Breyna based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Stiolto Respimat but not Breyna, including UnitedHealthcare
Sign up to reveal the full AI analysis
Breyna
Stiolto Respimat
At A Glance
Oral inhalation
Twice daily
ICS/LABA combination
Oral inhalation
Once daily
LAMA/LABA
Indications
  • Asthma
  • Chronic Obstructive Airway Disease
  • Bronchitis, Chronic
  • Pulmonary Emphysema
  • Chronic Obstructive Airway Disease
  • Bronchitis, Chronic
  • Pulmonary Emphysema
Dosing
Asthma (12 years and older) 2 inhalations of 80 mcg/4.5 mcg or 160 mcg/4.5 mcg twice daily by oral inhalation; starting dose based on asthma severity.
Asthma (6 to <12 years) 2 inhalations of 80 mcg/4.5 mcg twice daily by oral inhalation.
Chronic Obstructive Airway Disease, Bronchitis, Chronic, Pulmonary Emphysema 2 inhalations of 160 mcg/4.5 mcg twice daily by oral inhalation.
Chronic Obstructive Airway Disease, Bronchitis, Chronic, Pulmonary Emphysema Two inhalations once-daily at the same time of day via the STIOLTO RESPIMAT inhaler; do not use more than two inhalations every 24 hours.
Contraindications
  • Primary treatment of status asthmaticus or other acute episodes of asthma or COPD where intensive measures are required
  • Hypersensitivity to any ingredient in BREYNA
  • Use of LABA without inhaled corticosteroid in patients with asthma
  • Hypersensitivity to tiotropium, ipratropium, olodaterol, or any component of this product
Adverse Reactions
Most common (>=3%) Nasopharyngitis, headache, upper respiratory tract infection, pharyngolaryngeal pain, sinusitis, oral candidiasis, bronchitis, influenza
Serious Serious asthma-related events (hospitalizations, intubations, death), cardiovascular and CNS effects, Candida albicans infection, pneumonia or lower respiratory tract infections in COPD, immunosuppression, hypercorticism, adrenal suppression
Postmarketing Angina pectoris, tachycardia, atrial fibrillation, cataract, glaucoma, oropharyngeal candidiasis, anaphylactic reaction, hyperglycemia, hypokalemia, tremor, dysphonia, hypotension, hypertension
Most common (>3%) nasopharyngitis, cough, back pain
Serious COPD exacerbation, pneumonia
Pharmacology
Budesonide is an inhaled corticosteroid that suppresses inflammation by inhibiting multiple cell types and mediators involved in allergic and non-allergic inflammation; formoterol is a long-acting selective beta2-adrenergic agonist that relaxes bronchial smooth muscle by stimulating adenyl cyclase and increasing intracellular cyclic AMP.
Stiolto Respimat combines tiotropium, a long-acting muscarinic antagonist that inhibits M3-receptors at airway smooth muscle to produce bronchodilation, and olodaterol, a LABA that activates beta2-adrenoceptors to stimulate cAMP synthesis and relax airway smooth muscle cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Breyna
  • Covered on 5 commercial plans
  • PA (1/12) · Step Therapy (0/12) · Qty limit (11/12)
View full coverage details ›
Stiolto Respimat
  • Covered on 5 commercial plans
  • PA (4/12) · Step Therapy (0/12) · Qty limit (11/12)
View full coverage details ›
UnitedHealthcare
Breyna
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
View full coverage details ›
Stiolto Respimat
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (0/8) · Qty limit (7/8)
View full coverage details ›
Humana
Breyna
  • Covered on 0 commercial plans
  • PA (1/3) · Step Therapy (0/3) · Qty limit (1/3)
View full coverage details ›
Stiolto Respimat
  • Covered on 0 commercial plans
  • PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
View full coverage details ›
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Breyna.
No savings programs available for Stiolto Respimat.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
  • Verify eligibility with the payer.
  • Pull the right PA forms directly from the payer.
  • Submit, track & send live updates to your dashboard.
Utilize patient records to autofill forms with our AI in seconds.
Free to start · HIPAA compliant
Next Steps for Your Patient
BreynaView full Breyna profile
Stiolto RespimatView full Stiolto Respimat profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.